• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

PKC-delta targeted treatment of proliferative vitreoretinopathy

Research Project

Project/Area Number 24791862
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Ophthalmology
Research InstitutionOita University

Principal Investigator

YOKOYAMA Katsuhiko  大分大学, 医学部, 助教 (90464461)

Project Period (FY) 2012-04-01 – 2015-03-31
Project Status Completed (Fiscal Year 2014)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords増殖硝子体網膜症 / PKC δ / TGF-β / RPE / Ⅰ型コラーゲン / 眼生化学 / 眼分子生物学 / 増殖性硝子体網膜症 / PKC-δ / TGF-β2 / PKC-δ阻害剤 / 網膜色素上皮細胞
Outline of Final Research Achievements

Proliferative vitreoretinopathy (PVR) is severe complication after surgery of rhegmatogenous retinal detachment. Proliferative membrane, which is formed in the vitreous cavity and on the inner or outer surfaces of the neural retina, causes of PVR. It is thought that retinal pigment epithelium (RPE) cells could contribute to formation of proliferative membrane through production of collagen. In this study, we focused on PKC-δ which specifically express in proliferative membrane and analyzed about role of PKC-δ on collagen production system in RPE cells. For in vitro experiment, human RPE cell line (ARPE-19) was used. As results, we clarified that PKC-δ increase the typeⅠ collagen production in ARPE-19 cells. We expect that our findings contribute to development of novel therapeutic medicine targeting PKC-δ for PVR.

Report

(4 results)
  • 2014 Annual Research Report   Final Research Report ( PDF )
  • 2013 Research-status Report
  • 2012 Research-status Report

URL: 

Published: 2013-05-31   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi